ClinicalTrials.Veeva
Menu

Find clinical trials for Heart Disease in Valencia, VC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Heart Diseases
Cardiovascular Diseases
Heart Failure
Coronary Artery Disease
Myocardial Ischemia
Aortic Valve Stenosis
Heart Valve Diseases

Heart Disease trials near Valencia, VC, ESP:

Transition to KPL-387 Monotherapy Dosing & Administration Study

The primary objective of this study is to characterize the efficacy and safety of dosing regimens used to transition from prior pericarditis therapie...

Enrolling
Heart Diseases
Pericarditis
Drug: KPL-387

Phase 2

Kiniksa Pharmaceuticals International, plc

Valencia, Spain and 43 other locations

Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation (AVANT GUARD)

The purpose of this study is to establish the safety and effectiveness of pulsed field ablation as a first-line ablation treatment for subjects with...

Active, not recruiting
Persistent Atrial Fibrillation
Device: FARAPULSE™ Pulsed Field Ablation (PFA) System
Drug: Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone
Boston Scientific
Boston Scientific

Valencia, Spain and 60 other locations

Treatment of Functionally Non-significant Vulnerable Plaques in Patients With Multivessel ST-elevation Myocardial Infarction The VULNERABLE Trial

tomography (OCT) findings indicative of vulnerable plaque, in patients with ST-elevation myocardial infarction (STEMI) and multivessel disease...

Active, not recruiting
Ischemic Heart Disease
Coronary Artery Disease
Other: FFR>0.80+ OCT with findings indicative of vulnerable plaque
Fundación EPIC

Valencia, Spain and 49 other locations

Locations recently updated

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation...

Enrolling
Chronic Kidney Disease
Atherosclerosis Cardiovascular Disease
Drug: Orforglipron
Drug: Placebo

Phase 3

Lilly
Lilly

Valencia, Spain and 559 other locations

ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease

This study is for adults aged 18 years and older who have a type of fatty liver disease called metabolic dysfunction-associated steatotic li...

Begins enrollment this month
Metabolic Dysfunction-associated Steatotic Liver Disease
Obesity
Combination Product: Survodutide
Combination Product: Placebo matching survodutide

Phase 3

Boehringer Ingelheim
Boehringer Ingelheim

Valencia, Spain and 10 other locations

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications o...

Active, not recruiting
Atherosclerotic Cardiovascular Disease (ASCVD)
Chronic Kidney Disease (CKD)
Drug: Retatrutide
Drug: Placebo

Phase 3

Lilly
Lilly

Valencia, Spain and 762 other locations

Locations recently updated

A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk (ACCLAIM-CTA)

in your blood. People with high Lp(a) have a higher risk for heart disease. The main purpose of the study is to investigate how lep...

Enrolling
Cardiovascular Diseases
Lipoprotein(a)
Drug: Lepodisiran
Drug: Placebo

Phase 3

Lilly
Lilly

Valencia, Spain and 57 other locations

REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels

This study will look at the effects of CagriSema on cardiovascular events (for example heart attack and stroke) in people living with cardio...

Active, not recruiting
Cardiovascular Disease
Drug: Cagrilintide
Drug: Semaglutide

Phase 3

Novo Nordisk
Novo Nordisk

Valencia, Spain and 639 other locations

Status recently updated

The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD

population with better kidney function, demonstrated that the efficacy of the SGLT2 inhibitor dapagliflozin in reducing cardiovascular, heart...

Invitation-only
Active, not recruiting
Heart Failure
Kidney Disease, Chronic
Drug: Dapagliflozin 10 mg/day (oral)
Drug: Placebo

Phase 3

University Medical Center Groningen (UMCG)

Valencia, Spain and 101 other locations

AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications

in participants with type 2 diabetes who are at higher risk of heart and blood vessel problems and are already taking 1 to 3 diabetes medica...

Enrolling
Cardiovascular Risk
Type 2 Diabetes
Drug: Zenagamtide
Drug: Insulin glargine U-100

Phase 3

Novo Nordisk
Novo Nordisk

Valencia, Spain and 330 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems